ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Vaughn DW, Hoke CH Jr, 1992. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 14: 197–221.
-
2.
Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S, 1985. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis 151: 1093–1099.
-
3.
Chanama S, Sukprasert W, Sa-ngasang A, An A, Sangkitporn S, Kurane I, Anantapreecha S, 2005. Detection of Japanese encephalitis (JE) virus-specific IgM in cerebrospinal fluid and serum samples from JE patients. Jpn J Infect Dis 58: 294–296.
-
4.
Solomon T, Ooi MH, Beasley DW, Mallewa M, 2003. West Nile encephalitis. BMJ 326: 865–869.
-
5.
WHO, 2007. Manual for the Laboratory Diagnosis of Japanese Encephalitis Virus Infection. Geneva: World Health Organization.
-
6.
Jacobson JA, Hills SL, Winkler JL, Mammen M, Thaisomboonsuk B, Marfin AA, Gibbons RV, 2007. Evaluation of three immunoglobulin M antibody capture enzyme-linked immunosorbent assays for diagnosis of Japanese encephalitis. Am J Trop Med Hyg 77: 164–168.
-
7.
Ravi V, Desai A, Balaji M, Apte MP, Lakshman L, Subbakrishna DK, Sridharan G, Dhole TN, Ravikumar BV, 2006. Development and evaluation of a rapid IgM capture ELISA (JEV-Chex) for the diagnosis of Japanese encephalitis. J Clin Virol 35: 429–434.
-
8.
Cuzzubbo AJ, Endy TP, Vaughn DW, Solomon T, Nisalak A, Kalayanarooj S, Dung NM, Warrilow D, Aaskov J, Devine PL, 1999. Evaluation of a new commercially available immunoglobulin M capture enzyme-linked immunosorbent assay for diagnosis of Japanese encephalitis infections. J Clin Microbiol 37: 3738–3741.
-
9.
Shrivastva A, Tripathi NK, Parida M, Dash PK, Jana AM, Lakshmana Rao PV, 2008. Comparison of a dipstick enzyme-linked immunosorbent assay with commercial assays for detection of Japanese encephalitis virus-specific IgM antibodies. J Postgrad Med 54: 181–185.
-
10.
WHO 2006. WHO-recommended standards for surveillance of selected vaccine preventable diseases. Geneva: WHO.
-
11.
Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT, 2002. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol 9: 544–549.
-
12.
Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT, 2000. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38: 1823–1826.
-
13.
Lanciotti RS, Tsai TF, 2007. Arboviruses. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 1486–1500.
-
14.
Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, Roehrig JT, Gubler DJ, 2003. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306: 170–180.
-
15.
Purdy DE, Chang GJ, 2005. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology 333: 239–250.
-
16.
Lindsey HS, Calisher CH, Mathews JH, 1976. Serum dilution neutralization test for California group virus identification and serology. J Clin Microbiol 4: 503–510.
-
17.
Beaty BJ, Calisher CH, Shope RE, 1995. Diganostic procedures for viral, rickettsial and chlamydial infections. Lennette EH, Lennette DL, Lennette ET, eds. Arboviruses. Washington, DC: American Public Health Association, 465–478.
-
18.
Chambers TJ, Nestorowicz A, Mason PW, Rice CM, 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73: 3095–3101.
-
19.
Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP, 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75: 7290–7304.
-
20.
Pugachev KV, Guirakhoo F, Mitchell F, Ocran SW, Parsons M, Johnson BW, Kosoy OL, Lanciotti RS, Roehrig JT, Trent DW, Monath TP, 2004. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg 71: 639–645.
-
21.
Johnson BW, Kosoy O, Hunsperger E, Beltran M, Delorey M, Guirakhoo F, Monath T, 2009. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol 16: 1052–1059.
-
22.
Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE, 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70: 37–43.
-
23.
WHO, 2007. Guidelines for Plaque Reduction Neutralizing Testing of Human Antibodies to Dengue Viruses. Geneva: WHO.
-
24.
Ravi V, Robinson JS, Russell BJ, Desai A, Ramamurty N, Featherstone D, Johnson BW, 2009. Evaluation of IgM antibody capture enzyme-linked immunosorbent assay kits for detection of IgM against Japanese encephalitis virus in cerebrospinal fluid samples. Am J Trop Med Hyg 81: 1144–1150.
-
25.
Wilson EB, 1927. Probable inference the law of succession and statistical inference. J Am Stat Assoc 22: 209–212.
-
26.
May WL, Johnson WD, 1997. Confidence intervals for differences in correlated binary proportions. Stat Med 16: 2127–2136.
-
27.
May WL, Johnson WD, 1998. Hypothesis testing and confidence interval construction in 2 × 2 tables of correlated proportions. J Biopharm Stat 8: 115–130.
-
28.
Mabey D, Peeling RW, Ustianowski A, Perkins MD, 2004. Diagnostics for the developing world. Nat Rev Microbiol 2: 231–240.
-
29.
Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S, 1985. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis 151: 1093–1099.
-
30.
A-Nuegoonpipat A, Panthuyosri N, Anantapreecha S, Chanama S, Sa-Ngasang A, Sawanpanyalert P, Kurane I, 2008. Cross-reactive IgM responses in patients with dengue or Japanese encephalitis. J Clin Virol 42: 75–77.
-
31.
Burke DS, Nisalak A, Ussery MA, 1982. Antibody capture immunoassay detection of Japanese encephalitis virus immunoglobulin M and G antibodies in cerebrospinal fluid. J Clin Microbiol 16: 1034–1042.
-
32.
Roehrig JT, Johnson AJ, Hunt AR, Bolin RA, Chu MC, 1990. Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology 177: 668–675.
-
33.
Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT, 2002. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol 9: 544–549.
-
34.
Roehrig JT, 2003. Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141–175.
-
35.
Roehrig JT, Mathews JH, Trent DW, 1983. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128: 118–126.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 445 | 402 | 51 |
| Full Text Views | 328 | 13 | 1 |
| PDF Downloads | 96 | 8 | 1 |
Evaluation of Three Commercially Available Japanese Encephalitis Virus IgM Enzyme-Linked Immunosorbent Assays
Jaimie S. Robinson
Jaimie S. Robinson
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Jaimie S. Robinson in
Current site
Google Scholar
PubMed
Search for other papers by Jaimie S. Robinson in
Current site
Google Scholar
PubMed
David Featherstone
David Featherstone
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by David Featherstone in
Current site
Google Scholar
PubMed
Search for other papers by David Featherstone in
Current site
Google Scholar
PubMed
Ravi Vasanthapuram
Ravi Vasanthapuram
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Ravi Vasanthapuram in
Current site
Google Scholar
PubMed
Search for other papers by Ravi Vasanthapuram in
Current site
Google Scholar
PubMed
Brad J. Biggerstaff
Brad J. Biggerstaff
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Brad J. Biggerstaff in
Current site
Google Scholar
PubMed
Search for other papers by Brad J. Biggerstaff in
Current site
Google Scholar
PubMed
Anita Desai
Anita Desai
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Anita Desai in
Current site
Google Scholar
PubMed
Search for other papers by Anita Desai in
Current site
Google Scholar
PubMed
Nalini Ramamurty
Nalini Ramamurty
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Nalini Ramamurty in
Current site
Google Scholar
PubMed
Search for other papers by Nalini Ramamurty in
Current site
Google Scholar
PubMed
Anwarul Haque Chowdhury
Anwarul Haque Chowdhury
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Anwarul Haque Chowdhury in
Current site
Google Scholar
PubMed
Search for other papers by Anwarul Haque Chowdhury in
Current site
Google Scholar
PubMed
Hardeep S. Sandhu
Hardeep S. Sandhu
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Hardeep S. Sandhu in
Current site
Google Scholar
PubMed
Search for other papers by Hardeep S. Sandhu in
Current site
Google Scholar
PubMed
Kathleen F. Cavallaro
Kathleen F. Cavallaro
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Kathleen F. Cavallaro in
Current site
Google Scholar
PubMed
Search for other papers by Kathleen F. Cavallaro in
Current site
Google Scholar
PubMed
Barbara W. Johnson
Barbara W. Johnson
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, Colorado; Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland; Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India; Immunization and Vaccine Development, World Health Organization–South-East Asia Regional Office (WHO–SEARO), New Delhi, India; National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Global Immunization Division, Atlanta, Georgia
Search for other papers by Barbara W. Johnson in
Current site
Google Scholar
PubMed
Search for other papers by Barbara W. Johnson in
Current site
Google Scholar
PubMed
We evaluated performance of three commercial Japanese encephalitis virus (JEV) IgM antibody capture enzyme-linked immunosorbent assay (MAC ELISA) kits with a panel of serological specimens collected during a surveillance project of acute encephalitis syndrome in India and acute meningitis and encephalitis syndrome in Bangladesh. The serum and cerebral spinal fluid specimens had been referred to the Centers for Disease Control and Prevention (CDC) for confirmatory testing. The CDC results and specimen classifications were considered the reference standard. All three commercial kits had high specificity (95–99.5%), but low sensitivities, ranging from 17–57%, with both serum and cerebrospinal fluid samples. Specific factors contributing to low sensitivity compared with the CDC ELISA could not be determined through further analysis of the limits and dilution end points of IgM detection.
Author Notes
Authors' addresses: Jaimie S. Robinson, Brad J. Biggerstaff, and Barbara W. Johnson, Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, Fort Collins, CO, E-mails: fxa3@cdc.gov, BBiggerstaff@cdc.gov, and bfj9@cdc.gov. David Featherstone, Expanded Programme on Immunization/Immunization, Vaccines and Biologicals Department/Family and Child Health Cluster/World Health Organization, Geneva, Switzerland, E-mail: featherstoned@who.int. Ravi Vasanthapuram and Anita Desai, Department of Neurovirology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India, E-mails: virusravi@gmail.com and adesai@gmail.com. Nalini Ramamurty, World Health Organization - South-East Asia Regional Office I.P. Estate, New Delhi, India, E-mail: Ramamurtyn@SEARO.WHO.INT. Anwarul Haque Chowdhury, National Polio and Measles Laboratory, IPH, Dhaka, Bangladesh, E-mail: banplab@gmail.com. Hardeep S. Sandhu and Kathleen F. Cavallaro, CORP Bldg, Atlanta, GA, E-mails: hsandhu@cdc.gov and kfc1@cdc.gov.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Vaughn DW, Hoke CH Jr, 1992. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 14: 197–221.
-
2.
Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S, 1985. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis 151: 1093–1099.
-
3.
Chanama S, Sukprasert W, Sa-ngasang A, An A, Sangkitporn S, Kurane I, Anantapreecha S, 2005. Detection of Japanese encephalitis (JE) virus-specific IgM in cerebrospinal fluid and serum samples from JE patients. Jpn J Infect Dis 58: 294–296.
-
4.
Solomon T, Ooi MH, Beasley DW, Mallewa M, 2003. West Nile encephalitis. BMJ 326: 865–869.
-
5.
WHO, 2007. Manual for the Laboratory Diagnosis of Japanese Encephalitis Virus Infection. Geneva: World Health Organization.
-
6.
Jacobson JA, Hills SL, Winkler JL, Mammen M, Thaisomboonsuk B, Marfin AA, Gibbons RV, 2007. Evaluation of three immunoglobulin M antibody capture enzyme-linked immunosorbent assays for diagnosis of Japanese encephalitis. Am J Trop Med Hyg 77: 164–168.
-
7.
Ravi V, Desai A, Balaji M, Apte MP, Lakshman L, Subbakrishna DK, Sridharan G, Dhole TN, Ravikumar BV, 2006. Development and evaluation of a rapid IgM capture ELISA (JEV-Chex) for the diagnosis of Japanese encephalitis. J Clin Virol 35: 429–434.
-
8.
Cuzzubbo AJ, Endy TP, Vaughn DW, Solomon T, Nisalak A, Kalayanarooj S, Dung NM, Warrilow D, Aaskov J, Devine PL, 1999. Evaluation of a new commercially available immunoglobulin M capture enzyme-linked immunosorbent assay for diagnosis of Japanese encephalitis infections. J Clin Microbiol 37: 3738–3741.
-
9.
Shrivastva A, Tripathi NK, Parida M, Dash PK, Jana AM, Lakshmana Rao PV, 2008. Comparison of a dipstick enzyme-linked immunosorbent assay with commercial assays for detection of Japanese encephalitis virus-specific IgM antibodies. J Postgrad Med 54: 181–185.
-
10.
WHO 2006. WHO-recommended standards for surveillance of selected vaccine preventable diseases. Geneva: WHO.
-
11.
Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT, 2002. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol 9: 544–549.
-
12.
Martin DA, Muth DA, Brown T, Johnson AJ, Karabatsos N, Roehrig JT, 2000. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 38: 1823–1826.
-
13.
Lanciotti RS, Tsai TF, 2007. Arboviruses. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 1486–1500.
-
14.
Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, Roehrig JT, Gubler DJ, 2003. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306: 170–180.
-
15.
Purdy DE, Chang GJ, 2005. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology 333: 239–250.
-
16.
Lindsey HS, Calisher CH, Mathews JH, 1976. Serum dilution neutralization test for California group virus identification and serology. J Clin Microbiol 4: 503–510.
-
17.
Beaty BJ, Calisher CH, Shope RE, 1995. Diganostic procedures for viral, rickettsial and chlamydial infections. Lennette EH, Lennette DL, Lennette ET, eds. Arboviruses. Washington, DC: American Public Health Association, 465–478.
-
18.
Chambers TJ, Nestorowicz A, Mason PW, Rice CM, 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73: 3095–3101.
-
19.
Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP, 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75: 7290–7304.
-
20.
Pugachev KV, Guirakhoo F, Mitchell F, Ocran SW, Parsons M, Johnson BW, Kosoy OL, Lanciotti RS, Roehrig JT, Trent DW, Monath TP, 2004. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg 71: 639–645.
-
21.
Johnson BW, Kosoy O, Hunsperger E, Beltran M, Delorey M, Guirakhoo F, Monath T, 2009. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol 16: 1052–1059.
-
22.
Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE, 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70: 37–43.
-
23.
WHO, 2007. Guidelines for Plaque Reduction Neutralizing Testing of Human Antibodies to Dengue Viruses. Geneva: WHO.
-
24.
Ravi V, Robinson JS, Russell BJ, Desai A, Ramamurty N, Featherstone D, Johnson BW, 2009. Evaluation of IgM antibody capture enzyme-linked immunosorbent assay kits for detection of IgM against Japanese encephalitis virus in cerebrospinal fluid samples. Am J Trop Med Hyg 81: 1144–1150.
-
25.
Wilson EB, 1927. Probable inference the law of succession and statistical inference. J Am Stat Assoc 22: 209–212.
-
26.
May WL, Johnson WD, 1997. Confidence intervals for differences in correlated binary proportions. Stat Med 16: 2127–2136.
-
27.
May WL, Johnson WD, 1998. Hypothesis testing and confidence interval construction in 2 × 2 tables of correlated proportions. J Biopharm Stat 8: 115–130.
-
28.
Mabey D, Peeling RW, Ustianowski A, Perkins MD, 2004. Diagnostics for the developing world. Nat Rev Microbiol 2: 231–240.
-
29.
Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S, 1985. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis 151: 1093–1099.
-
30.
A-Nuegoonpipat A, Panthuyosri N, Anantapreecha S, Chanama S, Sa-Ngasang A, Sawanpanyalert P, Kurane I, 2008. Cross-reactive IgM responses in patients with dengue or Japanese encephalitis. J Clin Virol 42: 75–77.
-
31.
Burke DS, Nisalak A, Ussery MA, 1982. Antibody capture immunoassay detection of Japanese encephalitis virus immunoglobulin M and G antibodies in cerebrospinal fluid. J Clin Microbiol 16: 1034–1042.
-
32.
Roehrig JT, Johnson AJ, Hunt AR, Bolin RA, Chu MC, 1990. Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology 177: 668–675.
-
33.
Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT, 2002. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol 9: 544–549.
-
34.
Roehrig JT, 2003. Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141–175.
-
35.
Roehrig JT, Mathews JH, Trent DW, 1983. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128: 118–126.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 445 | 402 | 51 |
| Full Text Views | 328 | 13 | 1 |
| PDF Downloads | 96 | 8 | 1 |